NVO vs TCRT: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. NVO and TCRT share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined NVO and TCRT exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Novo Nordisk (NVO) is a Danish pharmaceutical company and a global leader in diabetes and obesity care. Its franchise centers on GLP-1 receptor agonists, most notably semaglutide, sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management. Novo Nordisk also holds a long-standing leadership position in insulin and broader diabetes therapies, and maintains smaller franchises in rare blood and endocrine disorders. The company is headquartered in Bagsvaerd, Denmark, and is controlled by the Novo Nordisk Foundation through a dual-share structure. US investors typically access it through the NVO American Depositary Receipt listed on the New York Stock Exchange, which represents the Danish B shares. The explosive demand for GLP-1 drugs for both diabetes and weight loss has made Novo Nordisk one of Europe's most valuable companies, while also straining its manufacturing capacity for injectable medicines.

Full NVO guide

Alaunos Therapeutics, formerly Ziopharm Oncology, spent years as a clinical-stage cancer cell-therapy company developing T-cell receptor (TCR-T) therapies for solid tumors. In 2023 it wound down its sole clinical study and cut most of its workforce, prioritizing its hunTR neoantigen-TCR discovery platform and exploring strategic alternatives. By 2026 the company had pivoted again, repositioning itself as a preclinical obesity and metabolic-disorders company centered on ALN1003, an oral small-molecule candidate that it describes as a non-hormonal, non-incretin approach (different from GLP-1 drugs). It has reported early preclinical, animal-model data suggesting weight and metabolic effects, but the program is pre-human, so there is no clinical proof of safety or efficacy in people, and no product revenue.

Full TCRT guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• NVO drivers: GLP-1 obesity and diabetes demand; Pipeline and next-generation candidates.
• TCRT drivers: Obesity and metabolic pivot (ALN1003); Non-hormonal, non-incretin differentiation.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Novo Nordisk is heavily concentrated in a single drug class, so any clinical setback, safety signal, or faster-than-expected competition from Eli Lilly's tirzepatide (Mounjaro, Zepbound) and newer entrants directly threatens the core franchise. For TCRT, the risks here are severe and existential, and outweigh the typical risks of a normal stock.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick NVO if you believe its drivers more; TCRT if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the NVO and TCRT guides.

NVO. Novo Nordisk has historically commanded a premium pharma multiple on the strength of GLP-1 growth and very high margins. The multiple is sensitive to GLP-1 market-share dynamics versus Eli Lilly, supply progress, and US pricing news; disappointing trial data or share loss can compress it quickly. All figures are approximate, are reported in Danish kroner and translated to dollars, and should be verified against the latest filings.

TCRT. All figures are approximate and tied to the asOf date; verify live numbers before acting, because a company in this condition can change rapidly through dilution, a reverse split, a financing, or delisting. Traditional valuation is not meaningful here: with no revenue, near-zero cash, and going-concern and delisting risk, the stock is priced on survival odds and speculation, not on earnings or assets. A very low share price does not make it cheap.

Headline figures (approximate, early 2026): NVO shows revenue (ttm) ~$40 billion (approximate, verify; reported in Danish kroner), operating margin ~45% (approximate, verify), net margin ~35% (approximate, verify), glp-1 share of revenue Majority of sales from semaglutide products (approximate); TCRT shows revenue trend No product revenue; the company is preclinical with its lead obesity candidate. Any income is incidental, not from product sales., profitability Deeply unprofitable, as expected for a preclinical biotech; ongoing net losses and cash burn with no near-term path to earnings., balance sheet About $0.35 million in cash as of March 31, 2026, with runway estimated only into Q2 2026 and going-concern risk. Verify the latest cash position, which can change quickly., nasdaq listing status Received an April 2026 deficiency notice for failing the $2.5 million minimum stockholders' equity rule; at risk of delisting pending a remediation plan..

NVO and TCRT are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined NVO and TCRT exposure against your real portfolio. It is not an investment adviser.